Latest Clinical Trials
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies St. Jude Children's Research Hospital NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Effect of Hydralazine on Alzheimer's Disease Shahid Sadoughi University of Medical Sciences and Health Services NA
COMPLETED
(Sep 1, 2026)
PHASE3 Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) Artios Pharma Ltd NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. AstraZeneca NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors Varun Monga, MBBS NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors BeOne Medicines NA
RECRUITING
(Sep 1, 2026)
PHASE1 First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer Accent Therapeutics NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors IDEAYA Biosciences NA
RECRUITING
(Sep 1, 2026)
PHASE1 Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy National Cancer Institute (NCI) NA
RECRUITING
(Sep 1, 2026)
PHASE2 Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis Fábio Fernandes NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations National Cancer Institute (NCI) NA
RECRUITING
(Aug 12, 2026)
PHASE1, PHASE2 Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers National Cancer Institute (NCI) NA
COMPLETED
(Aug 1, 2026)
PHASE1, PHASE2 Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors National Cancer Institute (NCI) NA
TERMINATED
(Aug 1, 2026)
PHASE2 Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia St. Jude Children's Research Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE1 RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW) MedTrace Pharma A/S NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 TT-702 in Patients With Advanced Solid Tumours. Cancer Research UK NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) SwanBio Therapeutics, Inc. NA
TERMINATED
(Aug 1, 2026)
PHASE1, PHASE2 Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector University of California, Los Angeles NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Surgical Pembro +/- Olaparib w TMZ for rGBM L. Nicolas Gonzalez Castro, MD, PhD NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency Inozyme Pharma NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer NRG Oncology NA
RECRUITING
(Aug 1, 2026)
PHASE3 Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors Gilead Sciences NA
RECRUITING
(Aug 1, 2026)
PHASE1 Exogenous Ketone Supplementation in ICU Delirium Vanderbilt University Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor Ankit Mangla, MD NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 VG081821AC Tablets for Early to Mid-stage Parkinson's Disease Zhejiang Vimgreen Pharmaceuticals, Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 The Use of Photobiomodulation in the Treatment of Spasticity After Stroke. University of Nove de Julho NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors Bayer NA
RECRUITING
(Jul 23, 2026)
PHASE1, PHASE2 Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. AstraZeneca NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer National Cancer Institute (NCI) NA
TERMINATED
(Jul 1, 2026)
PHASE1, PHASE2 Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma Melanoma Institute Australia NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. Massachusetts General Hospital NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer AstraZeneca NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study University of Michigan NA
COMPLETED
(Jul 1, 2026)
PHASE2 Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors MOMA Therapeutics NA
RECRUITING
(Jul 1, 2026)
PHASE1 Study of GS-2426 in Participants With Advanced Solid Tumors Gilead Sciences NA
RECRUITING
(Jul 1, 2026)
PHASE1 Enhancing Rehabilitation in Aging Study (ERAS) University of Florida NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis. Newsoara Biopharma Co., Ltd. NA
COMPLETED
(Jul 1, 2026)
PHASE3 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Centre Hospitalier Universitaire de Nice NA
COMPLETED
(Jun 1, 2026)
PHASE3 The Revitalize Study in Older Adults at Risk for Alzheimer's Disease University of Florida NA
COMPLETED
(Jun 1, 2026)
PHASE2 Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer University of Alabama at Birmingham NA
WITHDRAWN
(Jun 1, 2026)
PHASE1 Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer Cambridge University Hospitals NHS Foundation Trust NA
RECRUITING
(Jun 1, 2026)
PHASE2 A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction University of Leicester NA
COMPLETED
(Jun 1, 2026)
PHASE2, PHASE3 Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression University of Utah NA
RECRUITING
(Jun 1, 2026)
PHASE3 Immunosurveillance for Metastatic Colorectal Cancer MIPO Clinic NA
COMPLETED
(Jun 1, 2026)
PHASE2, PHASE3 A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion Bristol-Myers Squibb NA
RECRUITING
(Jun 1, 2026)
PHASE1 A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) Bristol-Myers Squibb NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 Montefiore Medical Center NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia University of California, Irvine NA
TERMINATED
(May 1, 2026)
PHASE2 CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) St. Jude Children's Research Hospital NA
RECRUITING
(May 1, 2026)
PHASE1 B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) St. Jude Children's Research Hospital NA
RECRUITING
(May 1, 2026)
PHASE1 A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer Regeneron Pharmaceuticals NA
TERMINATED
(May 1, 2026)
PHASE2 Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia Milestone Pharmaceuticals Inc. NA
COMPLETED
(May 1, 2026)
PHASE3 XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Xencor, Inc. NA
COMPLETED
(May 1, 2026)
PHASE2 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) Amgen NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. Cantargia AB NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) Phanes Therapeutics NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Fudan University NA
RECRUITING
(May 1, 2026)
PHASE2 Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Jonsson Comprehensive Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). Amgen NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) Amgen NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer Riboscience, LLC. NA
RECRUITING
(May 1, 2026)
PHASE2 Cord Blood Transplantation in Children and Young Adults With Blood Cancer Memorial Sloan Kettering Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis North American Consortium for Histiocytosis NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression MedSIR NA
RECRUITING
(Apr 1, 2026)
PHASE2 ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients Institut Curie NA
RECRUITING
(Apr 1, 2026)
PHASE3 Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma Riboscience, LLC. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer The Methodist Hospital Research Institute NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries. NHS National Waiting Times Centre Board NA
RECRUITING
(Mar 1, 2026)
PHASE2 Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury Randy Trumbower, PT, PhD NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep Baylor College of Medicine NA
COMPLETED
(Mar 1, 2026)
PHASE3 
